Targeting ocular malignancies using a novel light-activated virus-like drug conjugate

Area of Science:

• Ophthalmology
• Oncology
• Nanotechnology
• Immunotherapy

Background:

• Ocular malignancies pose treatment challenges, with current therapies risking vision loss.
• Targeted drug delivery using nanoparticles offers a promising alternative.
• Belzupacap sarotalocan (Bel-sar) is a novel virus-like particle-photosensitizer conjugate for targeted therapy.

Purpose of the Study:

• To review the application of Bel-sar in pre-clinical and clinical studies for ocular malignancies.
• To discuss Bel-sar's potential in treating uveal and conjunctival melanoma.
• To explore Bel-sar's combination with immunotherapy and its effects on tumor types and immune responses.

Main Methods:

• Review of pre-clinical and clinical studies involving Bel-sar.
• Analysis of Bel-sar's efficacy on pigmented and non-pigmented ocular tumors.
• Investigation of Bel-sar's impact on macrophage polarization and immune response.

Main Results:

• Bel-sar demonstrates targeted delivery, minimizing off-target effects.
• Photodynamic therapy with Bel-sar effectively treats diverse ocular tumors.
• Bel-sar induces immunogenic cell death, activating local and systemic immune responses.

Conclusions:

• Bel-sar is a promising targeted drug carrier for ocular tumors.
• Combining Bel-sar photodynamic therapy with immunotherapy enhances treatment efficacy.
• Further clinical investigation of Bel-sar is warranted for ocular malignancy treatment.